with 10% FBS; PC3 in Kaighn's F12K medium supplemented with 10% FBS; and HeLa and HEK293 in DMEM supplemented with 10% FBS. All cell lines were incubated in a humidifi ed atmosphere of 5% CO 2 at 37°C.
Cell proliferation assay with CCK-8 reagent
Cell proliferation rate was determined with Cell Counting Kit-8 (CCK-8) according to the manufacturer's protocol (Dojindo Laboratories), which is a sensitive colorimetric assay for viable cells.
PI staining and FACS analysis
Trypsinized cells were washed with 1× PBS and kept in 70% ethanol for one day for fi xation. Fixed cells were washed with 1× PBS twice and incubated with propodium iodide (PI) solution (0.1% Nonidet P-40, 100 g/ml RNase, and 200 g/l PI) for 10 min. Stained cells were analyzed by FACSCalibur TM (BD Biosciences), and the number of the cells in each stage was calculated with the ModFit LT TM cell cycle analysis program (Verity Software House) according to the manufacturer's instructions.
Oil Red O staining
Oil Red O stock solution was prepared in propylene glycol (0.7 g/100ml) and heated to 100°C for 10 min. DMSO or T0901317-treated cells were fi xed with 10% formaldehyde-containing PBS for 15 min and washed with PBS twice. Then cells were soaked in 100% propylene glycol and stained with Oil Red O stock solution for 30 min. Stained cells were washed with 85% propylene glycol and distilled water until the background became clear. Images were captured with EVOS ® ORIGINAL microscope (Advanced Microscopy Group) and NIKON TMS inverted microscope (NIKON).
RNA isolation and real-time quantitative PCR
As described earlier ( 24 ) , total RNA was isolated with TRIzol reagent (Invitrogen). Then equal amounts of RNA were subjected to cDNA synthesis by using RevertAid M-MuLV reverse transcriptase (Fermentas). The relative amount of mRNA was evaluated by MyIQ real-time quantitative PCR detection system (Bio-Rad Laboratories) and calculated following normalization to the GAPDH mRNA. The primer sequences that were used for the real-time quantitative PCR analyses are described in supplementary Table I .
Small-interference RNA transfection
Small-interference RNA (siRNA) duplexes for SREBP1 and FAS were designed by Dharmacon and produced from GenePharma. RWPE1 cells were transfected with Lipofectamine-2000 TM reagent (Invitrogen) according to the manufacturer's protocol. The sequence information for siRNA is described in supplementary Table II .
Protein isolation and Western blotting
The cells were lysed with NETN buffer [100 mM NaCl, 1 mM EDTA, 20 mM Tris-HCl (pH 8.0), 0.5% Nonidet P-40 and Complete TM protease inhibitor cocktail (Roche)] and subjected to Western blotting as described previously ( 13 ) . Briefl y, equal amounts of the proteins were separated by SDS-PAGE and transferred to PVDF (polyvinylidene difl uoride) membranes (Millipore). After transfer, the membranes were blocked with 4% nonfat milk and probed with primary antibodies. The primary antibodies used in Western blotting were ␤ -tubulin, cyclin A, cyclin B1, cyclin D1, cyclin E, cyclin H, and Rb 1, which were provided by Sigma. The SREBP1 antibody was produced by LabFrontier using 1-403 construct of SREBP1c as an immunogen. The results were visualized hepatic steatosis and hypertriglyceridemia through the enhancement of de novo fatty acid synthesis, which is accomplished by the induction of key lipogenic genes, such as SREBP1c and FAS (10) (11) (12) . Furthermore, it has been reported that chronic activation of LXR contributes to lipotoxicity and apoptosis in pancreatic ␤ -cells through hyperactivation of lipogenesis ( 13 ) . Due to unwanted potent lipogenic effect of T0901317, GW3965, another LXR ligand, has been developed ( 14 ) . GW3965 exhibits a much milder effect on lipogenic activity of LXR, even though GW3965 selectively activates LXR to maintain cholesterol effl ux.
Recently, other roles of LXR have been reported. Activation of LXR suppresses innate immunity by inhibiting the expression of infl ammatory genes, such as inducible nitric oxide synthase (iNOS), cyclooxygenase 2 (COX2), and interleukin-6 (IL6), in response to bacterial infection or lipopolysaccharide (LPS) stimulation ( 15, 16 ) . Moreover, LXR ␣ / ␤ -null macrophages reveal enhanced apoptosis after microbial infection due to defects of LXR-dependent target gene expression, implying that LXR would be important for macrophage survival and innate immune response ( 16 ) .
Several reports suggest that LXR is involved in proliferation of several cell types, such as smooth muscle cell, insulin-secreting MIN6 cell, and prostate-originated cancer cell lines (17) (18) (19) (20) (21) . Although it has been reported that LXR activation is associated with regulation of p27 and Smad3, the underlying molecular mechanism is largely unknown for cell cycle regulation. In the current study, we have extensively examined the effect of activated LXR on cell proliferation. Activation of LXR by its ligands induced G1/S arrest and attenuated cell proliferation in certain cells, such as RWPE1, THP1, SNU15, LNCaP, and HepG2 cells, but not in PC3, HeLa, and HEK293 cells. We further investigated the molecular mechanisms that are associated with LXR-induced cell cycle arrest. Collectively, our data suggest that lipogenic activity of activated LXR is important for the inhibition of cell proliferation and cell cycle progression.
MATERIAL AND METHODS

Reagents
T0901317 and GW3965 were purchased from Calbiochem and Sigma, respectively. Propodium iodide, Oil Red O, and mevalonic acid lactone was provided by Sigma. Mevalonic acid lactone was dissolved in 0.1 mol/l sodium hydroxide to convert lactone into sodium mevalonate. Then, the product was heated at 50°C for 2 h and adjusted to pH 7.4, as described previously ( 22, 23 esized that activated LXR might differentially regulate target gene expression depending on cell type. This idea was explored by examining the patterns of target gene expression on LXR ligands in various cells.
In RWPE1, THP1, SNU16, LNCaP, and HepG2 cells whose proliferations were sensitively suppressed by activated LXR, most LXR target genes, including ABCA1, ABCG1, SREBP1c, and FAS, were signifi cantly upregulated with horseradish peroxidase-conjugated secondary antibodies (Sigma) and enhanced chemiluminescence (Pierce) by using LAS-3000 imaging system (Fujifi lm).
RESULTS
LXR activation suppressed cell proliferation
To test whether activated LXR is involved in cell proliferation, T0901317, a synthetic LXR ligand, was treated into various cell lines, and we monitored their proliferation rate. As shown in Fig. 1A , the proliferation of certain cells, such as RWPE1, THP1, SNU16, LNCaP, and HepG2 was dose-dependently inhibited by activated LXR with T0901317. On the contrary, proliferation of PC3, HEK293, and HeLa was not affected by T0901317 ( Fig. 1B ) . Consistently, results of CCK-8 assay, which is a colorimetric method to measure the number of viable cells, also revealed that cell proliferation of RWPE1 and LNCaP, but not PC3, was diminished by LXR ligand ( Fig. 1C ) , implying that inhibitory effect of LXR activation on cell proliferation appears to be limited in certain cell types.
Recent studies have reported that a high dose of T0901317 is able to unexpectedly stimulate other nuclear hormone receptors, such as FXR and PXR, although T0901317 is more potent in activating LXR ( 25, 26 ) . To ascertain whether the inhibitory effect of T0901317 on cell proliferation is mediated by activated LXR, we used another LXR agonist, GW3965. GW3965 has been developed as a more specifi c ligand for LXR, and it hardly infl uences the transcriptional activities of other nuclear hormone receptors, including FXR and PXR ( 14 ) . When GW3965 was treated to RWPE1 cells, cell proliferation was significantly suppressed in a dose-dependent manner (supplementary Fig. I ). Similarly, we observed antiproliferative activity of GW3965 in LNCaP cells (supplementary Fig. II) , suggesting that activation of LXR would repress cell growth and proliferation in certain cells.
LXR activation induces G1/S arrest
Because LXR activation mitigates the proliferation rate in certain cells, we further investigated whether LXR activation would modulate cell cycle progression. When we analyzed the cell cycle distribution via fl ow cytometry analysis, we discovered that LXR ligand T0901317 increased the population in the G1 phase and decreased the population in the S phase in RWPE1, THP1, SNU16, and LNCaP cells ( Fig. 2A ). Both T0901317 and GW3965 arrested LNCaP cells at G1/S boundary in a dose-dependent manner (supplementary Fig. II-C) . However, LXR activation did not change the cell cycle status in PC3, HEK293, or HeLa cells ( Fig. 2B ). These results suggest that activation of LXR in certain cell types would prevent cell cycle progression into the S phase by inducing G1/S arrest, eventually leading to downregulation of cell proliferation in certain cell types.
Differential regulation of target gene expression by LXR
Because activation of LXR exhibited antiproliferative effects in certain cells, but not in all cell types, we hypoth- 
Mevalonate treatment does not affect ligand-induced cell cycle inhibition
LXR plays a key role in both cholesterol and fatty acid metabolism. Recently, it has been shown that LXR is able to repress T cell proliferation through regulation of LXRdependent sterol metabolism ( 27 ) . In T cells, induction of ABCG1 is essential for inhibitory effects of LXR, and treatment with mevalonate, a precursor for cholesterol, nullifi es antiproliferative property of LXR activation.
Because proliferation of RWPE1 cells were sensitively repressed by LXR ligands, we treated RWPE1 cells with mevalonate in the absence or presence of LXR ligands, such as T0901317 and GW3965, to test whether control of by the LXR ligand. However, in HEK293 and HeLa cells, expression of LXR target genes was barely changed by LXR activation ( Fig. 3 ) . Interestingly, although proliferation of PC3 cells was not signifi cantly altered by the LXR ligand, expression of ABCA1 and ABCG1 mRNAs was greatly stimulated by the LXR ligand in PC3 cells. However, the levels of SREBP1c and FAS mRNA were not signifi cantly infl uenced by the LXR ligand in PC3 cells. These results imply that expression pattern of fatty acid metabolism-related genes, such as SREBP1c and FAS, appears to be more tightly associated with the suppression of cell proliferation by LXR activation rather than cholesterol metabolism-related genes. ( Fig. 6A and  supplementary Fig. III) . Although suppression of SREBP1 via siRNA (hSREBP1_2394) did not signifi cantly affect the antiproliferative property of activated LXR, suppression of FAS via siRNA (hFAS_6089) partially, but substantially, recovered the cell proliferation activity in the presence of LXR ligands ( Fig. 6B-E ) . Consistent with these results, the population of positive cells stained with Oil Red O was decreased in FAS-knockdown cells, but not signifi cantly in SREBP1c-suppressed cells ( Fig. 6F ) . Further, when other siRNA against SREBP1 (hSREBP1_3278 and hSREBP1_2493) and FAS (hFAS_6124 and hFAS_6428) were tested on target gene expression, cell proliferation, and lipid accumulation, we observed similar results (supplementary Fig. III) . These data imply that FAS might be more crucial to mediate the effect of activated LXRdependent cell cycle arrest in certain cells. Despite these data, we could not completely exclude the possibility that SREBP1c is not involved in activated LXR-dependent antiproliferation due to the technical limitation of achieving suffi cient suppression of SREBP1 via siRNA.
Expression level of cyclin A was decreased by LXR ligands
Cell cycle regulation is affected by key cell cycle-related genes, such as cyclins and cdk inhibitors. To investigate the molecular mechanism of LXR-dependent cell cycle arrest in selective cells, we intensively examined the levels of several cyclins, cdc25a phosphatase, cdk inhibitors, cell cycle-related transcription factors, and their target genes by analyses with cDNA microarrays and qPCR. For assessing gene expression profi les, we primarily compared LNCaP with PC3 cells, because these cells represent activated LXR-sensitive and LXR-insensitive antiproliferation, respectively. The mRNA level of cyclin A and cdc25a were selectively decreased by activated LXR in LNCaP cells without signifi cant changes in mRNA levels of other cyclins, such as A1, B1, D1, and E, whereas none of them were altered in PC3 cells ( Fig. 7A , C ) . In accordance with these cholesterol metabolism might be involved in the inhibitory effect of LXR activation on cell proliferation. Unlike T cells, mevalonate did not overcome the inhibitory effect of the LXR ligands on cell proliferation ( Fig. 4A , C ) . Further, CCK-8 assays indicated that treatment of mevalonate did not reverse the cell cycle arrest by LXR ligands, even in a high concentration ( Fig. 4B, D ) . These data suggest that regulation of cholesterol metabolism by LXR activation might be independent of cell proliferation, except for T cells.
Control of lipogenesis is involved in antiproliferative effect of activated LXR
Next, we examined whether lipogenic activity of activated LXR is linked with an antiproliferative property. In RWPE1 cells, both T0901317 and GW3965 treatment greatly promoted positive cells stained with Oil Red O ( Fig. 5A ) , refl ecting the induction of de novo fatty acid synthesis by elevating the levels of accumulated neutral lipids, such as triacylglycerides and cholesterol esters. Similarly, other cell lines, including THP1 and HepG2, remarkably increased triacylglyceride accumulation upon LXR activation ( Fig. 5B ) . On the contrary, HeLa and HEK293 cells, which are insensitive cell types for the antiproliferative action of stimulated LXR, did not elevate lipid accumulation ( Fig. 5B ) , suggesting that lipogenic activity induced by LXR activation appears to play a key role in the antiproliferative effect.
To mediate lipogenic stimulation upon LXR activation, it is well known that there are two crucial LXR target genes. One is SREBP1c which is a key transcription factor for several downstream lipogenic genes, such as FAS, ACC, and SCD1, as well as insulin signaling (28) (29) (30) (31) . The other is FAS, which directly facilitates the synthesis of long chain fatty acids, and known to be modulated in both LXRdependent and LXR-independent manners ( 11 ). To test whether SREBP1c and/or FAS might be a key mediator for cell cycle arrest by LXR activation, we suppressed these genes via siRNA. Each RNAi construct exhibited ‫ف‬ 40-50% were able to promote expression of cholesterol effl ux genes ( Fig. 3 ) . Second, the number of Oil Red O-stained positive cells in the presence of LXR ligands was only elevated in activated LXR-dependent cell cycle-arrested cells ( Fig. 5 ) . Third, treatment of mevalonate, which is a precursor of cholesterol, did not rescue the RWPE1 cells from activated LXR-induced cell cycle arrest ( Fig. 4 ) . Lastly, suppression of FAS via siRNA partially diminished the inhibitory effect of activated LXR on cell proliferation ( Fig. 6 ) , implying that upregulation of FAS might be important for activated LXR-induced cell cycle arrest, at least in part. To ascertain whether inhibition of FAS would relieve LXRinduced cell cycle arrest, we treated the cells with cerulenin, a well-known FAS inhibitor. However, we failed to optimize experimental conditions because cerulenin exhibited potent cytotoxicity, which is well-known in many cells (32) (33) (34) (35) . Consistently, previous reports have suggested that cerulenin would be a lead compound for an anticancer drug due to its potent antiproliferative property (32) (33) (34) (35) .
It appears that LXR-dependent antiproliferation is regulated by several mechanisms based on cell type and context. Consistent with our data, recent studies have reported that LXR is involved in antiproliferation in several cells (17) (18) (19) (20) (21) . In T cells, LXR activation inhibits cell proliferation via cholesterol metabolism ( 27 ) . In addition, LXR affects cell cycle arrest by increasing p27 in smooth muscle cells, pancreatic ␤ -cells, and prostate cancer cells ( 17, 21, 36 ) . In this study, we did not observe upregulation of p27 mRNA or protein in the presence of LXR ligand ( Fig. 7 ; data not shown). Rather, we noticed that increase of de novo fatty acid synthesis appeared to be crucial for cell cycle arrest, supported by the results of differential regulation of LXR target genes and Oil Red O staining as well as FAS knockdown experiments. It is well-established that fi ndings, the protein level of cyclin A was decreased by the LXR ligand in LNCaP cells, but the protein level was not decreased in other cyclins, such as B1, D1, E, and H ( Fig.  7D ) . Simultaneously, when we examined the expression level of cdk inhibitor genes, such as p15, p21, and p27, there were minor changes in mRNA level of LNCaP cells. To ascertain these data, we also examined gene expression profi les in RWPE1 cells and obtained results similar to LNCaP cells ( Fig. 7B, E ) . These fi ndings indicate that cyclin A and cdc25a might be potential candidates to mediate activated LXR-induced antiproliferation in certain cell types.
DISCUSSION
In this study, we investigated the inhibitory effect of LXR activation on cell proliferation and cell cycle progression. We revealed that liganded LXR attenuated proliferation of certain cells through G1/S arrest, whereas the proliferation of other cell lines, such as PC3, HEK293, and HeLa, was not affected by LXR stimulation ( Figs. 1 and 2 ) . Gene expression pattern analyses in particular indicated that expression of lipogenic genes was closely associated with the antiproliferative effect of activated LXR ( Fig. 3 ) . Furthermore, knockdown of FAS partly relieved activated LXR-induced cell growth arrest ( Fig. 6 ) . However, the exact mechanism(s) involved in LXR-dependent cell cycle attenuation remains to be further investigated.
Interestingly, some of our data suggest that the regulation of fatty acid metabolism by LXR activation contributes to cell cycle inhibition. First, PC3, HEK293, and HeLa cells, which are insensitive to activated LXR-dependent antiproliferative effect, failed to induce expression of lipogenic genes such as SREBP1c and FAS, even though they phase and timing mitosis entry during the G2 phase (42) (43) (44) . Accordingly, the level of cyclin A is elevated in a variety of tumors, such as breast cancer, leukemia, and prostate cancer ( 42 ) . It remains to be investigated whether there is any correlation between lipotoxicity and cyclin A regulation upon LXR activation in certain cells. Cdc25a is another cell cycle-regulating gene encoding a tyrosine phosphatase, which is involved in the regulation of G1/S transition by activating cyclin A/Cdk2 and cyclin E/Cdk2 complexes through removal of inhibitory phosphorylations ( 45, 46 ) . Thus, it is possible that reduction of cdc25a also contributes to the inhibition of cell cycle progression at the G1/S checkpoint upon LXR activation. However, elevated fatty acid level confers lipotoxicity and even cell death, concomitant with G1/S arrest in certain cells (37) (38) (39) . For instance, RWPE1, macrophage, and pancreatic ␤ -cells are very active for lipid uptake and synthesis ( 37, 40, 41 ) , and uncontrolled lipogenic activity leads to antiproliferation and apoptosis in these cells (data not shown). Therefore, it is feasible that dysregulated lipid accumulation accompanied by increased lipogenic activity would be one of key mechanisms to mediate the antiproliferative effect of LXR activation.
The antiproliferative property of activated LXR is also linked to decreased levels of cyclin A and cdc25a. Cyclin A is essential for controlling DNA replication during the S Taken together, we propose that LXR may play a role in the regulation of cell proliferation as well as energy homeostasis. LXR activation actively attenuates cell cycle progression in certain cell types, such as RWPE1, THP1, SNU16, LNCaP, and HepG2, but not in others, such as PC3, HEK293, and HeLa cells. Further, we found that the inhibition of cell proliferation is associated with the lipogenic activity of LXR. These results provide new insight for the role of LXR on cell cycle control with lipogenic activity. the exact mechanism for cell cycle inhibition by LXR activation remains to be elucidated.
To explore the inhibition of cell proliferation by LXR ␣ and LXR ␤ , we examined the expression levels of LXR ␣ and LXR ␤ in various cell lines (supplementary Fig. IV) . Because most cells expressed substantial amounts of both LXR ␣ and LXR ␤ mRNA, we did not fi nd any correlation between LXR ␣ or LXR ␤ expression and cell cycle inhibition. Additionally, we investigated the effect of LXR ␣ and LXR ␤ suppression via siRNA in RWPE1 cells. Neither LXR ␣ nor LXR ␤ knockdown in RWPE1 cells failed to relieve antiproliferation in the presence of LXR ligands. Although we tested several LXR ␣ and LXR ␤ siRNA constructs (hLXR ␣ _934, hLXR ␣ _542, hLXR ␤ _508, and hLXR ␤ _1176), the knockdown effi ciency of LXR ␣ and LXR ␤ siRNA was only ‫ف‬ 40-50%, respectively (supplementary Fig. V) . Moreover, combined treatment of LXR ␣ and LXR ␤ siRNA did not improve the technical limitations of individual LXR knockdown (data not shown). When we examined the antiproliferative effect of LXR activation in mouse embryonic fi broblasts (MEF) from LXR ␣ -knockout ( ␣ KO), LXR ␤ -knockout ( ␤ KO), and LXR ␣ / ␤ -double knockout (DKO) mice, LXR activation with its ligands did not suppress proliferation rates in those MEF (supplementary Fig. VI-A) . Under the same conditions, we did not detect any dramatic change of lipid contents on LXR ligands in MEF (data not shown). However, we noted that expression of several LXR target genes was upregulated by LXR ligand in wild-type and LXR ␣ KO MEF (supplementary Fig. VI-B) . Thus, even though we propose that LXR activation with elevated lipogenic activity appears to play a role in mediating antiproliferation in certain cell types, future studies are essential to clarify whether LXR ␣ and/or LXR ␤ is crucial for LXR-dependent antiproliferation. , and PC3(C) cells were incubated with 5 M T0901317 for 18 h, and total RNA were isolated. After synthesizing cDNA from total RNA, mRNA expression levels of cyclin A, cyclin A1, cyclin B1, cyclin D1, cyclin E, cdc25a, p15, p21, p27, p27, p53, mdm2, gadd45a, and myc were analyzed by real-time quantitative PCR and normalized with GAPDH control. LNCaP(D) and RWPE1(E) cells were treated with 5 M T0901317 for one day, and total protein was subjected to Western blotting analysis. * P < 0.05; ** P = 0.146; ns, not signifi cant. Supplemental Material can be found at:
